Super-stable homogeneous iodinated formulation technology for improving the therapeutic effect of patients with advanced hepatocellular carcinoma.
Pan He,Furui Zhong,Bin Luo,Guosong Luo,Xuewen Wang,X. Xia,Bo Li
DOI: https://doi.org/10.21037/qims-20-741
2020-08-31
Quantitative Imaging in Medicine and Surgery
Abstract:Quant Imaging Med Surg 2020;10(11):2223-2226 | http://dx.doi.org/10.21037/qims-20-741 Liver cancer is one of the most common malignant tumors in China. Worldwide, the incidence of primary liver cancer is about 15.3/100,000 and the mortality rate is about 14.3/100,000. Among male patients who died of cancer in 2018, liver cancer was the second-leading cause of cancer death (1). At present, surgical resection of hepatocellular carcinoma (HCC), also referred to as partial hepatectomy, is still the first choice for the treatment of HCC (2). However, due to the growth characteristics of HCC, there are no obvious symptoms in the early stages. When symptoms, such as fever, liver pain, systemic inflammation and abdominal swelling appear, the disease has mostly developed to the middle and late stages, the tumor diameter is large, the rate of radical resection is low, and prognosis is poor. Massive liver tumors usually have a diameter of ≥10 cm, abundant blood supply, and tend to compress and invade the edge of the first, second or third hepatic hilum. Accordingly, their surgical removal involves a high degree of difficulty, large trauma, and more bleeding. They are often accompanied by satellite foci and intrahepatic microscopic cancer, with low surgical cure rate, which contribute to their postoperative relapse (3). Indeed, it has been reported that after the radical resection the 5-year survival rate of patients with massive liver cancer tumors has been only 12.2% to 29.3% (4). Therefore, how to downstage a massive HCC to improve the rate of surgical resection, and how to reduce the trauma during resection and the rate of postoperative recurrence are important research questions to improve the prognosis of patients with advanced HCC. Besides their large size and abundant blood supply, massive liver tumors have complex relationship with the surrounding structure with small residual liver volume after surgical removal (3). The surgical resection rate and postoperative effect can be improved by reducing preoperative tumor volume and reducing or blocking nourishing blood vessels around tumors so to increase disease-free l iver volume. At present, commonly used methods include conventional transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) (5). The second approach is to carefully evaluate the liver tumor and liver reserve function before surgery in order to select the appropriate Editorial Commentary
Medicine